ImmuPharma (LON:IMM) Shares Down 8.3% – Should You Sell?

ImmuPharma plc (LON:IMM) dropped 8.3% during mid-day trading on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). Approximately 7,864,863 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).

ImmuPharma Price Performance

The stock has a 50-day moving average price of GBX 2.46 and a two-hundred day moving average price of GBX 1.95. The stock has a market cap of £20.11 million, a PE ratio of -483.00 and a beta of 1.53.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.